WRBY

Warby Parker Inc. 2024 Annual Report (10-K) Summary

Business Context and Reporting Period

This filing is the Annual Report on Form 10-K for Warby Parker Inc. for the fiscal year ended December 31, 2024. Warby Parker is a mission-driven, public benefit corporation operating at the intersection of design, technology, healthcare, and social enterprise. The company sells eyewear products (glasses, sunglasses, contact lenses) and provides optical services (eye exams, vision tests) through an omnichannel model comprising 276 retail stores (271 in the U.S., 5 in Canada) and e-commerce platforms. As of December 31, 2024, the company employed 3,780 people.

Key Financial Metrics

Liquidity and Debt: The company maintains a $120.0 million revolving credit facility (2024 Credit Facility) with JPMorgan Chase, which remains undrawn except for $4.3 million in letters of credit. The facility includes an accordion feature to increase capacity to $175.0 million. The company has an accumulated deficit of $687.2 million as of December 31, 2024.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 15.2% year-over-year to $771.3 million, driven by a 7.8% increase in Active Customers and a rise in Average Revenue per Customer (ARPC) to $307 from $287. Growth was fueled by the adoption of precision progressives, lens replacement services, and higher-priced frames.
• Profitability Improvement: The net loss narrowed significantly to $20.4 million from $63.2 million in 2023. Adjusted EBITDA improved to $73.1 million, reflecting operational efficiencies and revenue growth.
• Margin Expansion: Gross margin expanded by 80 basis points to 55.3%, driven by faster growth in the high-margin glasses business and efficiencies in owned optical laboratories, partially offset by lower-margin contact lens sales growth.
• Expense Management: Selling, General, and Administrative (SG&A) expenses increased 4.5% in absolute dollars but decreased as a percentage of revenue from 65.3% to 59.2%. This was primarily due to a $23.2 million decrease in stock-based compensation expense related to the Founders Grant.
• Store Expansion: The retail footprint grew to 276 stores, with 236 offering in-person eye exams (up from 194 in 2023).

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management expects to continue investing in retail expansion, technology, and product innovation. The company anticipates operating losses may continue in the near term as it scales, though it believes existing cash and credit facilities are sufficient for at least the next 12 months.
• Key Risks:
  • Supply Chain & Tariffs: Reliance on a limited number of suppliers, particularly in China, exposes the company to tariffs and supply disruptions. New tariffs imposed in February 2025 on Chinese imports introduce uncertainty regarding future costs.
  • Regulatory Compliance: The company is subject to extensive healthcare regulations (HIPAA, FDA) and state-specific laws regarding the corporate practice of medicine and optometry. A 2018 cybersecurity incident resulted in a civil monetary penalty paid in December 2024, with the investigation closed in February 2025.
  • Competition: Intense competition from large integrated players (e.g., EssilorLuxottica) and independent retailers.
  • Profitability: The company has a history of losses and may not achieve or sustain profitability in the future.
• Unusual Items: The company settled a class action lawsuit regarding California wage and hour laws for $1.95 million in October 2024, subject to court approval. Stock-based compensation expense decreased significantly due to the vesting schedule of the Founders Grant.

Investor Verification Checklist

• Path to GAAP Profitability: Verify the timeline and specific cost-reduction strategies required to convert Adjusted EBITDA positivity into GAAP net income, given the persistent net losses.
• Tariff Impact Mitigation: Assess the effectiveness of the company's supply chain diversification strategies to offset the impact of new tariffs on Chinese imports announced in early 2025.
• Store Economics: Review the unit economics of new retail stores opened in 2024, specifically the time-to-profitability and contribution to overall free cash flow.
• Regulatory Exposure: Monitor ongoing compliance with state-specific "corporate practice of medicine" laws and any potential changes in FDA regulations regarding the Virtual Vision Test app.
• Stock-Based Compensation Volatility: Analyze the future trajectory of stock-based compensation expenses as the Founders Grant vesting schedule concludes and new equity awards are granted.